KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Jazz Pharmaceuticals (JAZZ) Enterprise Value (2016 - 2025)

Jazz Pharmaceuticals has reported Enterprise Value over the past 16 years, most recently at -$1.4 billion for Q4 2025.

  • Quarterly results put Enterprise Value at -$1.4 billion for Q4 2025, up 42.31% from a year ago — trailing twelve months through Dec 2025 was -$1.4 billion (up 42.31% YoY), and the annual figure for FY2025 was -$1.4 billion, up 42.31%.
  • Enterprise Value for Q4 2025 was -$1.4 billion at Jazz Pharmaceuticals, down from -$1.3 billion in the prior quarter.
  • Over the last five years, Enterprise Value for JAZZ hit a ceiling of -$490.8 million in Q1 2022 and a floor of -$2.4 billion in Q4 2024.
  • Median Enterprise Value over the past 5 years was -$1.3 billion (2023), compared with a mean of -$1.3 billion.
  • Biggest five-year swings in Enterprise Value: crashed 198.96% in 2021 and later skyrocketed 76.6% in 2022.
  • Jazz Pharmaceuticals' Enterprise Value stood at -$591.4 million in 2021, then tumbled by 49.04% to -$881.5 million in 2022, then tumbled by 70.88% to -$1.5 billion in 2023, then tumbled by 60.18% to -$2.4 billion in 2024, then soared by 42.31% to -$1.4 billion in 2025.
  • The last three reported values for Enterprise Value were -$1.4 billion (Q4 2025), -$1.3 billion (Q3 2025), and -$1.2 billion (Q2 2025) per Business Quant data.